Aptamer-functionalized liposomes for targeted cancer therapy

Moosavian, Seyedeh Alia; Sahebkar, Amirhossein

doi:10.1016/j.canlet.2019.01.045

Cited by 134 publications

(66 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several reviews are available, e.g. those by Shigdar [ 12 ], Zununi Vahed et al [ 13 ], and Moosavian et al [ 14 ], the latter of which covers aptamer-functionalized liposome platforms. Also, there is a book chapter by Eilers et al [ 15 ] titled Aptamer-Modified Nanoparticles in Medical Applications .…”

Section: Targeted Deliverymentioning

confidence: 99%

Recent advances in aptamer applications for analytical biochemistry

Zon

2022

Analytical Biochemistry

View full text Add to dashboard Cite

Aptamers are typically defined as relatively short (20–60 nucleotides) single-stranded DNA or RNA molecules that bind with high affinity and specificity to various types of targets. Aptamers are frequently referred to as “synthetic antibodies” but are easier to obtain, less expensive to produce, and in several ways more versatile than antibodies. The beginnings of aptamers date back to 1990, and since then there has been a continual increase in aptamer publications. The intent of the present account was to focus on recent original research publications, i.e., those appearing in 2019 through April 2020, when this account was written. A Google Scholar search of this recent literature was performed for relevance-ranking of articles. New methods for selection of aptamers were not included. Nine categories of applications were organized and representative examples of each are given. Finally, an outlook is offered focusing on “faster, better, cheaper” application performance factors as key drivers for future innovations in aptamer applications.

show abstract

Section: Targeted Deliverymentioning

confidence: 99%

Recent advances in aptamer applications for analytical biochemistry

Zon

2022

Analytical Biochemistry

View full text Add to dashboard Cite

show abstract

“…Aptamers are short, synthetic and single-stranded DNA or RNA molecules that can specifically bind to their targets with a high affinity. And aptamers have attracted broad interest in targeted drug delivery because of their high selectivity and affinity, low immunogenicity, easy synthesis with high reproducibility, facile modification, and relatively rapid tissue penetration with no toxicity 111, 112. Liang et al 113 used mouse OS cells (K7M2) as target cells to screen aptamers by cell-SELEX.…”

Section: Strategies For Osteosarcoma-targeted Drug Deliverymentioning

confidence: 99%

Recent advances of drug delivery nanocarriers in osteosarcoma treatment

Wang¹,

Hu²,

Qing³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Osteosarcoma is the most common primary malignant bone tumor mainly occurred in children and adolescence, and chemotherapy is limited for the side effects and development of drug resistance. Advances in nanotechnology and knowledge of cancer biology have led to significant improvements in developing tumor-targeted drug delivery nanocarriers, and some have even entered clinically application. Delivery of chemotherapeutic agents by functionalized smart nanocarriers could protect the drugs from rapid clearance, prolong the circulating time, and increase the drug concentration at tumor sites, thus enhancing the therapeutic efficacy and reducing side effects. Various drug delivery nanocarriers have been designed and tested for osteosarcoma treatment, but most of them are still at experimental stage, and more further studies are needed before clinical application. In this present review, we briefly describe the types of commonly used nanocarriers in osteosarcoma treatment, and discuss the strategies for osteosarcoma-targeted delivery and controlled release of drugs. The application of nanoparticles in the management of metastatic osteosarcoma is also briefly discussed. The purpose of this article is to present an overview of recent progress of nanoscale drug delivery platforms in osteosarcoma, and inspire new ideas to develop more effective therapeutic options.

show abstract

“…Se ha visto en trabajos anteriores, que los liposomas se introducen en el interior de las células por endocitosis, estos también nos sirven para proteger a los fármacos y que de esta forma puedan llegar a su lugar de acción sin sufrir ninguna modificación [45]. Los aptaméros son ácidos nucleicos de cadena sencilla, con una estructura tridimensional que les permite unirse con alta afinidad y especificidad a las moléculas diana [46].…”

Section: 1 å 26 åunclassified

“…Esta selectividad va a venir dada tanto por el análogo sintético de BMP2 utilizado, puesto que posee una alta afinidad por BMPR que estará sobreexpresado en las VICs, como por los aptámeros diseñados. Los aptámeros son cadenas monocatenarias de ácidos nucleicos con estructura tridimensional que les permite unirse con una alta afinidad a moléculas diana específicas [46]. Algunas de las moléculas diana que se podrían seleccionar para que los aptámeros se unan específicamente son: el receptor RANK, ɑsmootelina, el receptor Notch1 mutado o BMPR.…”

Section: Ensayo De Internalización De Los Liposomasunclassified

Diseño teórico de terapia combinada con un inhibidor de BMPR y un miRNA contra RUNX-2 en la Enfermedad de la Válvula Aórtica Calcificada

Isidro¹,

Torre-Rubio²,

Recio³

et al. 2020

DIANAS

View full text Add to dashboard Cite

Palabras clave: EVAC; Liposoma; BMP2; RUNX-2; miRNA; péptido-mimético Resumen La enfermedad de la válvula aórtica calcificada (EVAC) es una enfermedad caracterizada por la diferenciación de las células intersticiales de la válvula hacia un fenotipo pre-osteoblástico. Esta diferenciación celular produce una matriz calcificada, causando de esta forma un remodelaje tisular que conlleva a la estenosis aórtica y a una pérdida de la funcionalidad. Nuestro proyecto se enfoca en evitar la diferenciación osteoblástica inhibiendo la cascada de señalización de BMP2 y el factor de transcripción RUNX-2. Para ello planteamos el siguiente diseño teórico de la investigación que se realizaría para llevar a cabo el descubrimiento de 2 posibles fármacos empleados sinérgicamente en una terapia combinada.

show abstract

Aptamer-functionalized liposomes for targeted cancer therapy

Cited by 134 publications

References 104 publications

Recent advances in aptamer applications for analytical biochemistry

Recent advances in aptamer applications for analytical biochemistry

Recent advances of drug delivery nanocarriers in osteosarcoma treatment

Diseño teórico de terapia combinada con un inhibidor de BMPR y un miRNA contra RUNX-2 en la Enfermedad de la Válvula Aórtica Calcificada

Contact Info

Product

Resources

About